Novo Nordisk A/S
NYSE:NVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Novo Nordisk A/S
NYSE:NVO
|
DK |
|
Corbion NV
AEX:CRBN
|
NL |
|
A
|
Ascopiave SpA
SWB:AVA
|
IT |
|
H
|
Hana 33 Special Purpose Acquisition Co
KOSDAQ:475250
|
KR |
|
T
|
TechL Co Ltd
KOSDAQ:064520
|
KR |
Intrinsic Value
Is NVO undervalued or overvalued?
See the intrinsic value estimate for 
Novo Nordisk A/S and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
NVO looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with NVO’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Novo Nordisk A/S Does
Novo Nordisk is a global drug company best known for medicines that treat diabetes and obesity. It also sells treatments for rare blood disorders, growth hormone deficiency, and other chronic diseases. The company does not make consumer products; it develops prescription medicines that doctors prescribe and patients use over long periods.
- Headquarters
- Denmark DK
- Employees
- 47 792
- IPO date
- May 17, 1974
Novo Nordisk A/S has a wide economic moat
Legal protection for key medicines prevents rivals from selling direct copies in major markets, helping Novo Nordisk keep profits from its diabetes and obesity treatments. Competitors must develop different medicines and prove they work rather than simply copy its protected products.
Read the full moat analysis
Revenue & Expenses Breakdown
Novo Nordisk A/S
Earnings Waterfall
Novo Nordisk A/S
The intrinsic value for Novo Nordisk A/S (NVO) under the Base Case is hidden USD.
Compared with the current market price of 38.96 USD, the stock appears hidden.